Senetek lizensiert Invicorp in Europa !!! - 500 Beiträge pro Seite
eröffnet am 21.06.04 14:09:43 von
neuester Beitrag 31.07.04 06:54:36 von
neuester Beitrag 31.07.04 06:54:36 von
Beiträge: 6
ID: 872.194
ID: 872.194
Aufrufe heute: 0
Gesamt: 911
Gesamt: 911
Aktive User: 0
ISIN: US8172093077
Feedback
Senetek Licenses Invicorp(R) Erectile Dysfunction Treatment to Ardana for Europe
Ardana to Assume Full Regulatory Responsibility and Senetek to Receive
Royalties and Milestone Payments
NAPA, Calif., and EDINBURGH, Scotland, June 21 /PRNewswire-FirstCall/ -- Senetek PLC (Nasdaq: SNTK), a healthcare technologies company focused on developing and co-marketing products for the anti-aging markets worldwide, and Ardana, the emerging pharmaceutical company dedicated to improving reproductive health, today announced the signing of an exclusive license for Ardana to manufacture and market Invicorp(R), Senetek`s patented combination drug treatment for male erectile dysfunction, in the European Union and European Free Trade Area.
Under the license agreement, Ardana assumes full responsibility for completing the European drug regulatory process for Invicorp(R) and seeking national marketing approvals throughout Europe. Senetek will receive royalties based on net sales of Invicorp(R) plus milestone payments upon regulatory approvals in specified major markets and achievement of specified cumulative net sales in Europe.
Invicorp(R) has been approved in Denmark, which has been chosen as the Reference Member State for the Mutual Recognition Procedure in Europe. Additionally, Invicorp(R) has been approved in New Zealand where it will be marketed by another Senetek licensee commencing later this month.
Current pharmacotherapy for erectile dysfunction includes oral, transurethral and injectable intracavernosal treatments. The non-oral erectile dysfunction market was estimated as $85 million worldwide in 2003, with $45 million sales in Europe and $32 million in the US (Source: IMS MAT Sept 03). Invicorp(R) is an injectable form of phentolamine mesilate and vasoactive intestinal polypeptide.
Frank J. Massino, Chairman and Chief Executive Officer of Senetek, commented, "Finding the right commercial partner for this unique injectable formulation, with the focus it deserves and the technical expertise and financial capability to speed it to market, was a key objective of Senetek`s 2004 business plan, and Ardana is perfectly suited to that role. We are confident that our partnership with Ardana will allow Invicorp(R) to realize its full potential in the growing European erectile dysfunction market. With this agreement in place, Senetek is ideally positioned to concentrate on its core business of expanding its portfolio of proprietary dermatologicals for the global ethical pharmaceutical and cosmeceutical markets."
Dr. Maureen Lindsay, Chief Executive of Edinburgh-based Ardana, said, "Some patients are unsuited to an oral formulation and we believe the market for injectable treatments for erectile dysfunction will grow as awareness of the condition increases. Based on clinical data we also believe that Invicorp(R) can provide important benefits in the injectable treatment of erectile dysfunction. Invicorp(R), together with Striant(TM) SR, our testosterone replacement therapy for men with primary or secondary hypogonadism, which we recently launched in the UK, provide the basis for developing our franchise in male reproductive health, one of the areas we are focusing on through our specialist sales force. This deal represents the next milestone in our development as we build a portfolio of revenue generating products to take us through to profitability."
Senetek PLC is a life sciences-driven product development and licensing company focused on the high growth market for dermatological and skin care products primarily addressing photodamage and age-related skin conditions. Senetek`s patented compound Kinetin is a naturally occurring cytokinin that has proven effective in improving the appearance of aging skin with virtually none of the side effects associated with acid-based active ingredients. Senetek has licensed Kinetin to leading global and regional dermatological and skin care marketers including Valeant Pharmaceuticals, The Body Shop and Revlon, and recently announced the grant to Valeant Pharmaceuticals of rights to license Zeatin, a promising analogue of Kinetin currently in pre-clinical trials. Senetek`s researchers at the University of Aarhus, Denmark, also are collaborating with the Institute of Experimental Botany, Prague, and with Beiersdorf AG, Hamburg, to identify and evaluate additional new biologically active compounds for this high growth field. www.senetekplc.com.
Senetek PLC Investor Relations Contact:
1-707-226-3900 ext. 102
E-mail: Pknopick@eandecommunications.com
Ardana Limited is an emerging pharmaceutical company focused on reproductive health. It aims to become a leading source of clinical and commercial innovation in the $20 billion human reproductive health market, which is growing at 9% per annum. In addition to Striant(TM) SR, Ardana has a rich development portfolio including the Gonadotrophin Releasing Hormone (GnRH)-antagonist, Teverelix LA, in Phase II trials in patients with prostate cancer and benign prostate hyperplasia, Chronodyne(R) (terbutaline) which is in Phase I/II trials for endometriosis-related infertility (being developed in collaboration with Columbia Laboratories (Nasdaq: CBRX) and a reformulation of the GnRH analog `Leuprorelin` which is in Phase II trials for prostate cancer. www.ardana.co.uk.
Ardana`s therapeutic interests encompass androgen replacement, infertility, sexual dysfunction and obstetrics. The company has exclusive rights to commercialise research by the Medical Research Council (MRC)`s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland, which has been at the forefront of this area of research for the last 30 years. The HRSU contributes a plethora of early stage development compounds to the Ardana development portfolio, which complement later stage and marketed products. The MRC employs nearly 100 staff at the Unit, which currently receives total annual funding of 3.8 million pound Sterling.
Ardana has raised 43.4 million pound Sterling in four funding rounds. Ardana investors include DVC Deutsche Venture Capital, Albany Venture Managers Limited and 3i Bioscience Investment Trust, Merlin Biosciences Limited, MVM Limited (MVM), Techno Venture Management (TVM), ABN-AMRO Participates, 3i Group plc, ISIS Equity Partners plc, Scottish Widows Investment Partnership Ltd, Saffron Hill Ventures, Mitsubishi Corporation and Green Highlander, LLC.
Ardana to Assume Full Regulatory Responsibility and Senetek to Receive
Royalties and Milestone Payments
NAPA, Calif., and EDINBURGH, Scotland, June 21 /PRNewswire-FirstCall/ -- Senetek PLC (Nasdaq: SNTK), a healthcare technologies company focused on developing and co-marketing products for the anti-aging markets worldwide, and Ardana, the emerging pharmaceutical company dedicated to improving reproductive health, today announced the signing of an exclusive license for Ardana to manufacture and market Invicorp(R), Senetek`s patented combination drug treatment for male erectile dysfunction, in the European Union and European Free Trade Area.
Under the license agreement, Ardana assumes full responsibility for completing the European drug regulatory process for Invicorp(R) and seeking national marketing approvals throughout Europe. Senetek will receive royalties based on net sales of Invicorp(R) plus milestone payments upon regulatory approvals in specified major markets and achievement of specified cumulative net sales in Europe.
Invicorp(R) has been approved in Denmark, which has been chosen as the Reference Member State for the Mutual Recognition Procedure in Europe. Additionally, Invicorp(R) has been approved in New Zealand where it will be marketed by another Senetek licensee commencing later this month.
Current pharmacotherapy for erectile dysfunction includes oral, transurethral and injectable intracavernosal treatments. The non-oral erectile dysfunction market was estimated as $85 million worldwide in 2003, with $45 million sales in Europe and $32 million in the US (Source: IMS MAT Sept 03). Invicorp(R) is an injectable form of phentolamine mesilate and vasoactive intestinal polypeptide.
Frank J. Massino, Chairman and Chief Executive Officer of Senetek, commented, "Finding the right commercial partner for this unique injectable formulation, with the focus it deserves and the technical expertise and financial capability to speed it to market, was a key objective of Senetek`s 2004 business plan, and Ardana is perfectly suited to that role. We are confident that our partnership with Ardana will allow Invicorp(R) to realize its full potential in the growing European erectile dysfunction market. With this agreement in place, Senetek is ideally positioned to concentrate on its core business of expanding its portfolio of proprietary dermatologicals for the global ethical pharmaceutical and cosmeceutical markets."
Dr. Maureen Lindsay, Chief Executive of Edinburgh-based Ardana, said, "Some patients are unsuited to an oral formulation and we believe the market for injectable treatments for erectile dysfunction will grow as awareness of the condition increases. Based on clinical data we also believe that Invicorp(R) can provide important benefits in the injectable treatment of erectile dysfunction. Invicorp(R), together with Striant(TM) SR, our testosterone replacement therapy for men with primary or secondary hypogonadism, which we recently launched in the UK, provide the basis for developing our franchise in male reproductive health, one of the areas we are focusing on through our specialist sales force. This deal represents the next milestone in our development as we build a portfolio of revenue generating products to take us through to profitability."
Senetek PLC is a life sciences-driven product development and licensing company focused on the high growth market for dermatological and skin care products primarily addressing photodamage and age-related skin conditions. Senetek`s patented compound Kinetin is a naturally occurring cytokinin that has proven effective in improving the appearance of aging skin with virtually none of the side effects associated with acid-based active ingredients. Senetek has licensed Kinetin to leading global and regional dermatological and skin care marketers including Valeant Pharmaceuticals, The Body Shop and Revlon, and recently announced the grant to Valeant Pharmaceuticals of rights to license Zeatin, a promising analogue of Kinetin currently in pre-clinical trials. Senetek`s researchers at the University of Aarhus, Denmark, also are collaborating with the Institute of Experimental Botany, Prague, and with Beiersdorf AG, Hamburg, to identify and evaluate additional new biologically active compounds for this high growth field. www.senetekplc.com.
Senetek PLC Investor Relations Contact:
1-707-226-3900 ext. 102
E-mail: Pknopick@eandecommunications.com
Ardana Limited is an emerging pharmaceutical company focused on reproductive health. It aims to become a leading source of clinical and commercial innovation in the $20 billion human reproductive health market, which is growing at 9% per annum. In addition to Striant(TM) SR, Ardana has a rich development portfolio including the Gonadotrophin Releasing Hormone (GnRH)-antagonist, Teverelix LA, in Phase II trials in patients with prostate cancer and benign prostate hyperplasia, Chronodyne(R) (terbutaline) which is in Phase I/II trials for endometriosis-related infertility (being developed in collaboration with Columbia Laboratories (Nasdaq: CBRX) and a reformulation of the GnRH analog `Leuprorelin` which is in Phase II trials for prostate cancer. www.ardana.co.uk.
Ardana`s therapeutic interests encompass androgen replacement, infertility, sexual dysfunction and obstetrics. The company has exclusive rights to commercialise research by the Medical Research Council (MRC)`s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland, which has been at the forefront of this area of research for the last 30 years. The HRSU contributes a plethora of early stage development compounds to the Ardana development portfolio, which complement later stage and marketed products. The MRC employs nearly 100 staff at the Unit, which currently receives total annual funding of 3.8 million pound Sterling.
Ardana has raised 43.4 million pound Sterling in four funding rounds. Ardana investors include DVC Deutsche Venture Capital, Albany Venture Managers Limited and 3i Bioscience Investment Trust, Merlin Biosciences Limited, MVM Limited (MVM), Techno Venture Management (TVM), ABN-AMRO Participates, 3i Group plc, ISIS Equity Partners plc, Scottish Widows Investment Partnership Ltd, Saffron Hill Ventures, Mitsubishi Corporation and Green Highlander, LLC.
Senetek Retains Tri-Artisan Partners LLC to Seek Strategic Acquisitions
Wednesday July 21, 7:10 am ET
NAPA, Calif., July 21 /PRNewswire-FirstCall/ -- Senetek PLC (Nasdaq: SNTK - News) www.senetekplc.com, a healthcare technology company focused on developing and co-marketing products for the anti-aging markets worldwide, announced that at a special meeting on July 15th its Board of Directors unanimously approved retaining Tri-Artisan Partners LLC, a New York-based merchant bank, to assist the Company in expanding and diversifying its portfolio of proprietary technologies within its core businesses of skin care and dermatologicals through complementary acquisitions.
Tri-Artisan Partners LLC principally serves middle market companies by combining senior Wall Street expertise with a team of over 40 senior operating executives who are drawn from key industry sectors including the specialty pharmaceutical and medical device sectors. Roger C. Kahn, a Managing Director who has focused on the biotechnology, medical device and specialty pharmaceutical sectors over the course of his 23 year career on Wall Street, including senior positions at Bear Stearns and CIBC Oppenheimer, will lead the Tri-Artisan Partners team advising Senetek PLC.
Frank J. Massino, Chairman and Chief Executive Officer of Senetek, commented, "Tri-Artisan`s evaluation of Senetek`s strengths and needs complements the previously announced strategic course set by our Board and charted in our 2004 Business Plan, to strengthen and broaden our base of proprietary skincare and dermatological technologies while out-licensing our pharmaceuticals and disposing of non-core assets. We look forward to working with Tri-Artisan to identify and execute strategic transactions to speed our growth in the rapidly expanding skin care and dermatological sectors."
Langsam wird´s interessant, sieht so aus, als bereite das Management eine Übernahme vor. Das setzt voraus, dass genügend Geld in der Kasse ist. Ein gutes Zeichen.
Wednesday July 21, 7:10 am ET
NAPA, Calif., July 21 /PRNewswire-FirstCall/ -- Senetek PLC (Nasdaq: SNTK - News) www.senetekplc.com, a healthcare technology company focused on developing and co-marketing products for the anti-aging markets worldwide, announced that at a special meeting on July 15th its Board of Directors unanimously approved retaining Tri-Artisan Partners LLC, a New York-based merchant bank, to assist the Company in expanding and diversifying its portfolio of proprietary technologies within its core businesses of skin care and dermatologicals through complementary acquisitions.
Tri-Artisan Partners LLC principally serves middle market companies by combining senior Wall Street expertise with a team of over 40 senior operating executives who are drawn from key industry sectors including the specialty pharmaceutical and medical device sectors. Roger C. Kahn, a Managing Director who has focused on the biotechnology, medical device and specialty pharmaceutical sectors over the course of his 23 year career on Wall Street, including senior positions at Bear Stearns and CIBC Oppenheimer, will lead the Tri-Artisan Partners team advising Senetek PLC.
Frank J. Massino, Chairman and Chief Executive Officer of Senetek, commented, "Tri-Artisan`s evaluation of Senetek`s strengths and needs complements the previously announced strategic course set by our Board and charted in our 2004 Business Plan, to strengthen and broaden our base of proprietary skincare and dermatological technologies while out-licensing our pharmaceuticals and disposing of non-core assets. We look forward to working with Tri-Artisan to identify and execute strategic transactions to speed our growth in the rapidly expanding skin care and dermatological sectors."
Langsam wird´s interessant, sieht so aus, als bereite das Management eine Übernahme vor. Das setzt voraus, dass genügend Geld in der Kasse ist. Ein gutes Zeichen.
Napa, Kalifornien (ots/PRNewswire) -
Senetek PLC (Nasdaq: SNTK), Internetpräsenz www.senetekplc.com,
ist ein Technologie-Unternehmen des Gesundheitssektors, das sich mit
der Entwicklung und weltweiten Vermarktung von Produkten für den
Anti-Aging-Markt befasst. Das Unternehmen gab bekannt, dass der
Aufsichtsrat des Unternehmens auf einem Sondertreffen am 15 Juli
einheitlich beschlossen hat, eine Beziehung mit der Tri-Artisan
Partners LLC, einer in New York ansässigen Handelsbank, einzugehen.
Tri-Artisan Partners LLC wird dem Unternehmen helfen, sein
Portefeuille an proprietären Technologien im Kerngeschäft Hautpflege
und dermatologische Produkte durch ergänzende Akquisitionen zu
erweitern und zu diversifizieren.
Tri-Artisan Partners LLC hilft vor allem den Unternehmen des
Mittelmarktes, sowohl mit seiner tiefgreifenden Wall-Street-Expertise
als auch mit einem Team von über 40 gehobenen Betriebsleitern, die
aus wichtigen Industriesektoren, einschliesslich Spezialpharmaka und
medizinische Geräte, geworben wurden. Roger C. Kahn ist ein Managing
Director, der das Tri-Artisan Partners Team zur Beratung von Senetek
PLC leiten wird. Er hatte sich im Laufe seiner 23jährigen
Wall-Street-Karriere auf die Sektoren Biotechnologie, medizinische
Geräte und Spezialpharmaka spezialisiert und dabei gehobene
Positionen bei Bear Stearns und CIBC Oppenheimer innegehabt.
Frank J. Massino, der Vorstandsvorsitzende und CEO von Senetek,
kommentierte den Beschluss: "Die von Tri-Artisan durchgeführte
Bewertung der Stärken und Bedürfnisse von Senetek ergänzt die vom
Aufsichtsrat bereits angekündigte strategische Zielrichtung, die in
unserem Geschäftsplan für 2004 niedergelegt ist: Stärkung und
Verbreiterung unserer proprietären Hautpflege- und
Dermatologie-Technologien bei gleichzeitiger Lizenzierung unserer
pharmazeutischen Produkte sowie Beseitigung unserer nicht zum Kern
gehörenden Geschäfte. Wir sehen einer Zusammenarbeit mit Tri-Artisan
mit Freude entgegen, um die für unser schnelles Wachstum in den sich
rapide erweiternden Hautpflege- und Dermatologiesektoren strategisch
wichtigen Transaktionen zu identifizieren und auszuführen."
Senetek PLC (Nasdaq: SNTK), Internetpräsenz www.senetekplc.com,
ist ein Technologie-Unternehmen des Gesundheitssektors, das sich mit
der Entwicklung und weltweiten Vermarktung von Produkten für den
Anti-Aging-Markt befasst. Das Unternehmen gab bekannt, dass der
Aufsichtsrat des Unternehmens auf einem Sondertreffen am 15 Juli
einheitlich beschlossen hat, eine Beziehung mit der Tri-Artisan
Partners LLC, einer in New York ansässigen Handelsbank, einzugehen.
Tri-Artisan Partners LLC wird dem Unternehmen helfen, sein
Portefeuille an proprietären Technologien im Kerngeschäft Hautpflege
und dermatologische Produkte durch ergänzende Akquisitionen zu
erweitern und zu diversifizieren.
Tri-Artisan Partners LLC hilft vor allem den Unternehmen des
Mittelmarktes, sowohl mit seiner tiefgreifenden Wall-Street-Expertise
als auch mit einem Team von über 40 gehobenen Betriebsleitern, die
aus wichtigen Industriesektoren, einschliesslich Spezialpharmaka und
medizinische Geräte, geworben wurden. Roger C. Kahn ist ein Managing
Director, der das Tri-Artisan Partners Team zur Beratung von Senetek
PLC leiten wird. Er hatte sich im Laufe seiner 23jährigen
Wall-Street-Karriere auf die Sektoren Biotechnologie, medizinische
Geräte und Spezialpharmaka spezialisiert und dabei gehobene
Positionen bei Bear Stearns und CIBC Oppenheimer innegehabt.
Frank J. Massino, der Vorstandsvorsitzende und CEO von Senetek,
kommentierte den Beschluss: "Die von Tri-Artisan durchgeführte
Bewertung der Stärken und Bedürfnisse von Senetek ergänzt die vom
Aufsichtsrat bereits angekündigte strategische Zielrichtung, die in
unserem Geschäftsplan für 2004 niedergelegt ist: Stärkung und
Verbreiterung unserer proprietären Hautpflege- und
Dermatologie-Technologien bei gleichzeitiger Lizenzierung unserer
pharmazeutischen Produkte sowie Beseitigung unserer nicht zum Kern
gehörenden Geschäfte. Wir sehen einer Zusammenarbeit mit Tri-Artisan
mit Freude entgegen, um die für unser schnelles Wachstum in den sich
rapide erweiternden Hautpflege- und Dermatologiesektoren strategisch
wichtigen Transaktionen zu identifizieren und auszuführen."
Die Nachricht ist absolut negativ.
FM stösst an seine Grenzen. Er hat es über Jahre nicht fertig gebracht die guten Produkte ordentlich zu vermarkten. Das ist jetzt die Kapitulation. MAn hat ja jetzt genügend Cash um andere arbeiten zu lassen. Ich frage mich was die ganzen Board Mitglieder den ganzen Tag machen.
FM stösst an seine Grenzen. Er hat es über Jahre nicht fertig gebracht die guten Produkte ordentlich zu vermarkten. Das ist jetzt die Kapitulation. MAn hat ja jetzt genügend Cash um andere arbeiten zu lassen. Ich frage mich was die ganzen Board Mitglieder den ganzen Tag machen.
Umcka,
was die Board-Mitglieder machen ist die eine Sache. Da sind bestimmt einige faule Eier im Korb. Nur, dass man Dinge, die andere besser verstehen nach aussen vergibt, halte ich bei genauer Abwägung nicht für verkehrt. Also so ganz negativ sehe ich diese Nachricht nicht. Irgendwann und irgendwie muss es doch mit Senetek endlich mal wieder nach oben gehen.
Gruss
Fuchs
was die Board-Mitglieder machen ist die eine Sache. Da sind bestimmt einige faule Eier im Korb. Nur, dass man Dinge, die andere besser verstehen nach aussen vergibt, halte ich bei genauer Abwägung nicht für verkehrt. Also so ganz negativ sehe ich diese Nachricht nicht. Irgendwann und irgendwie muss es doch mit Senetek endlich mal wieder nach oben gehen.
Gruss
Fuchs
Trading Spotlight
Der Makler hat nachbörslich in weiser Voraussicht den Kurs auf 0,63 $ heraufgesetzt:
Real-Time Market / ECN Get Real-Time Market / ECN for:
SENETEK PLC (RTM/ECN)
Symbol: SNTK
Last Trade: 0.63 Jul 30
After Hours Change: 0.15 (31.25%)
Today`s Change: 0.18 (40.00%)
Bid: N/A
Ask: 0.63
This is a free Real-Time Market quote.
Each Real-Time Market quote is from a participating institution only ( Archipelago, INET, Knight) and does not necessarily represent the best bid or ask in the marketplace.
For complete streaming real-time quotes, charts, and screening for NASDAQ, NYSE, and Amex, upgrade to
Real-Time Market Tracker (Free Trial)
View: Combined | Archipelago | INET
COMBINED REAL-TIME ORDER BOOK
Bid Orders
Price Order Size Institution
No data available
Ask Orders
Price Order Size Institution
0.63 900 INET
0.68 5050 INET
0.72 3900 INET
0.75 4900 INET
0.82 3100 INET
0.85 2000 INET
0.95 3800 INET
0.96 500 INET
0.99 1000 INET
1.15 12600 INET
http://finance.yahoo.com/q/ecn?s=SNTK
Real-Time Market / ECN Get Real-Time Market / ECN for:
SENETEK PLC (RTM/ECN)
Symbol: SNTK
Last Trade: 0.63 Jul 30
After Hours Change: 0.15 (31.25%)
Today`s Change: 0.18 (40.00%)
Bid: N/A
Ask: 0.63
This is a free Real-Time Market quote.
Each Real-Time Market quote is from a participating institution only ( Archipelago, INET, Knight) and does not necessarily represent the best bid or ask in the marketplace.
For complete streaming real-time quotes, charts, and screening for NASDAQ, NYSE, and Amex, upgrade to
Real-Time Market Tracker (Free Trial)
View: Combined | Archipelago | INET
COMBINED REAL-TIME ORDER BOOK
Bid Orders
Price Order Size Institution
No data available
Ask Orders
Price Order Size Institution
0.63 900 INET
0.68 5050 INET
0.72 3900 INET
0.75 4900 INET
0.82 3100 INET
0.85 2000 INET
0.95 3800 INET
0.96 500 INET
0.99 1000 INET
1.15 12600 INET
http://finance.yahoo.com/q/ecn?s=SNTK
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,08 | |
| +0,24 | |
| -0,46 | |
| -0,15 | |
| -0,24 | |
| -0,34 | |
| -0,61 | |
| -1,18 | |
| -0,67 | |
| -0,69 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 96 | ||
| 46 | ||
| 45 | ||
| 33 | ||
| 32 | ||
| 27 | ||
| 21 | ||
| 19 | ||
| 19 | ||
| 18 |
